BEAM Stock Analysis: Buy, Sell, or Hold?
BEAM - Beam Therapeutics Inc. Common Stock
$34.79
1.31 (3.91%)
▲
5d:
+2.53%
30d:
+20.13%
90d:
+43.64%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.1/10
Get Alerted When BEAM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BEAM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BEAM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BEAM is currently trading at $34.79, which is considered extended relative to its 30-day fair value range of $29.94 to $34.14.
Technical Outlook: Technically, BEAM is in a uptrend. Immediate support is located at $32.66, while resistance sits at $36.88. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: BEAM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $51.07 (+46.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BEAM is in a uptrend. Immediate support is located at $32.66, while resistance sits at $36.88. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: BEAM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $51.07 (+46.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$29.94 -
$34.14
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 46.8% below Wall St target ($51.07)
Trading Range Analysis
30-Day Trading Range
$29.94 -
$34.14
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$32.66
Resistance Level
$36.88
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.33
Wall Street Target
$51.07
(+46.8%)
Revenue Growth (YoY)
324.9%
Profit Margin
-40.2%
Share & Embed Analysis
Last updated: July 03, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BEAM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Simon
SELL
6700 shares
2026-04-01
Christine Bellon
SELL
5956 shares
2026-04-01
Giuseppe Ciaramella
SELL
11810 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
Advanced BEAM Option Strategies
Professional options setups generated by AI based on today's BEAM price and gamma walls.
